VK

Venkata Krishna Sai Suryadevara

Active Director Director DIN 10797072
DIN 10797072 First appointment Oct 2024 Primary industry Paper
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Oct 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Venkata Krishna Sai Suryadevara

Data last updated:

Venkata Krishna Sai Suryadevara is a Director at Coastal Drugs Innovations Private Limited (since 2024). The company operates in Paper.

DIN 10797072
Primary Designation Director
Industry Paper
First Appointment 04 Oct 2024
Oldest Company Age 2 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director04 Oct 20242024Active

Board colleagues of Venkata Krishna Sai Suryadevara

Directorship timeline

Open interactive timeline →
Coastal Drugs Innovations Private Limited
Premium access

Shareholding and investment profile for Venkata Krishna Sai Suryadevara

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Venkata Krishna Sai Suryadevara

Venkata Krishna Sai Suryadevara currently holds 1 directorship: Coastal Drugs Innovations Private Limited (Director, since 04 Oct 2024).

Venkata Krishna Sai Suryadevara was first appointed on 04 Oct 2024 as Director at Coastal Drugs Innovations Private Limited.

The current boards of Venkata Krishna Sai Suryadevara's companies include Sreekanth Chappidi (Coastal Drugs Innovations Private Limited), Srinivasa Rao Chennupati (Coastal Drugs Innovations Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available